| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9268249 | Journal of Clinical Virology | 2005 | 8 Pages |
Abstract
Our results suggest that patients carrying either CCR2-64I or CXCL12 3â²A have a more favorable prognosis during HAART treatment.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Andrew M. Passam, Alexandros Zafiropoulos, Spiros Miyakis, Ioannis Zagoreos, Nikolaos G. Stavrianeas, Elias Krambovitis, Demetrios A. Spandidos,